50742-512 : Clofarabine 1 mg/ml Intravenous Injection, Solution


NDC: 50742-512
Labeler: Ingenus Pharmaceuticals, LLC
Product Type: Human Prescription Drug
Drug Name:  Clofarabine
Dosage Form: Intravenous Injection, Solution
Application #: ANDA210270
Rev. Date: 


NDC Package Codes:

  • 50742-512-20: 1 VIAL, SINGLE‑DOSE IN 1 CARTON (50742‑512‑20) > 20 ML IN 1 VIAL, SINGLE‑DOSE

Active Ingredients:

  • Clofarabine

Dosage Strength:

  • 1 mg/mL

Pharmaceutical Classes:

  • Nucleic Acid Synthesis Inhibitors [MoA]
  • Nucleoside Metabolic Inhibitor [EPC]

Related Products:

Based on records with the same trade name.
  • 0955-1746 Clofarabine 1 mg/ml Intravenous Injection by Sanofi-aventis U.S. LLC
  • 43598-309 Clofarabine 1 mg/ml Intravenous Injection by Dr.reddy's Laboratories Inc
  • 49315-003 Clofarabine 1 mg/ml Intravenous Injection by Cadila Healthcare Limited
  • 55150-326 Clofarabine 1 mg/ml Intravenous Injection by Eugia Us LLC
  • 60505-6166 Clofarabine 1 mg/ml Intravenous Injection by Apotex Corp.
  • 63323-572 Clofarabine 1 mg/ml Intravenous Injection by Fresenius-kabi
  • 67457-546 Clofarabine 1 mg/ml Intravenous Injection by Mylan Institutional LLC
  • 68083-386 Clofarabine 1 mg/ml Intravenous Injection by Gland Pharma Limited
  • 70121-1236 Clofarabine 1 mg/ml Intravenous Injection by Amneal Biosciences LLC
  • 71288-128 Clofarabine 1 mg/ml Intravenous Injection by Meitheal Pharmaceuticals Inc.
  • 72266-108 Clofarabine 1 mg/ml Intravenous Injection by Fosun Pharma USA Inc.

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 50742-512 QR Code

< Prev: 50742-505Next: 50742-513 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.